IDENTIFYING AND ASSESSING COMPLIANCE RISKS IN THE MANUFACTURING OF STERILE INJECTABLES WITHIN THE INDIAN PHARMACEUTICAL INDUSTRY

By

Ranjeeth Reddy Goli

A dissertation submitted in partial fulfilment of the requirements for MSc in Pharmaceutical Business & Technology

Griffith College Dublin

19th May 2024

CANDIDATE DECLARATION

I, Ranjeeth Reddy Goli certify that the information provided in this study is accurate to the best of my knowledge. I confirm that this research was carried out according to the Innopharma Griffith College's academic integrity standards. The results presented in this study are from my own work and are original. Any sources, including books, journals, websites, and articles used in this study are referenced and any work by others is not plagiarized.

Student's Name	Supervisor's Name
Ranjeeth Reddy Goli	**Dr Martin Barr**

Acknowledgement

I would like to express my appreciation to the University for allowing me to select this research topic for the completion of the course. I would also like to express my gratitude to my supervisor who guided me throughout my dissertation journey and steered me in the correct direction for success. Finally, I would like to convey my gratitude to my family members and colleagues for their continuous support and motivation to help me achieve my study goals.

Table of Contents

LIST OF FIGURES

LIST OF TABLES

ABSTRACT

The Indian Pharmaceutical industry is a global supplier of sterile injectable products, but in recent years, it has faced tougher regulations and demands for quality and compliance improvement. The research demonstrates that India is a major supplier of these life-saving drugs and hence authorities must seek strict compliance. The whole scheme relies on data collected from survey (surveys), and there was no in-depth analysis on the business factors that influence compliance. The purpose of the research is to raise the bar for sterile drug products quality and safety standards that are proactively identifying and rectifying compliance issues within the Indian pharmaceutical manufacturing systems.

This study is aimed at exploring the views and involvement of the Indian pharmaceutical sector in ensuring conformity with sterile injectable drug production regulations. Our findings demonstrate a mix of opinions on the current regulatory model, and some of the participants voice their belief, whilst others express doubts about the level of compliance. Most of the responses are positive in maintaining sterile conditions during manufacturing, which are assured owing to cGMP adherence, with cleanrooms strictly monitored. The analysis brings a positive response to quality control measures, particularly training and education of the staff. Businesses that focus on their employee training are typically associated with higher confidence in production processes, quality control and effectiveness in operations. In fact, it can be asserted that high-quality control rigour, trust in the maintenance of sterile conditions, and the right infrastructure design are tightly correlated with each other as well. Although a well-established majority of respondents are confident in data security and robust infrastructure design; some do have a little anxiety which hints at the possible existence of weaknesses or obsolescence of the structures. The outcome of the study emphasizes the need for reliable quality systems, performing training regularly, installing systems of data integrity control and upgrading facilities for the manufacture of aseptic drug products in India.

1 Introduction

1.1 Chapter Overview

As a major global provider of injectable products, the Indian pharmaceutical industry has recently been the subject of quality and safety worries by regulatory agencies. The main aim of the chapter will be to demonstrate the background and the context of the research. The aim and the objectives that were set will also be presented in the chapter. The justification for the conduction of the research will be explored and the significance that the result will have on the future of the Indian pharmaceutical industry will be demonstrated in detail. For every research, some limitations are observed, and the main limitations that were observed after the conduction of the research will be provided in this section. Finally the chapter will be concluded with a summary that will be responsible for summarizing the overall discussion carried out within the chapter.

1.2 Research Background

The Indian pharmaceutical market is the third biggest in terms of value and the third largest in terms of number. As a big maker of generic injectable sterile goods, it sends 20% of the world's generics exports (Sawant *et al.*, 2022). But in the last few years, regulatory bodies have been looking more closely at the business to make sure it meets quality and safety standards for sterile injectables.

The Drugs and Cosmetics Act of 1940 says that the Central Drugs Standard Control Organisation (CDSCO), which is part of the Ministry of Health and Family Welfare, is in charge of controlling drugs in India. Schedule M, which lists Good Manufacturing Practices (GMP), the Rules for Manufacture, Sale, and Distribution of Drugs, and advice papers from CDSCO are the main rules that control sterile injectables. For sterile products to be approved for sale, they must comply with Schedule M. Therefore if an injectable medicine needs for approval for circulation in the market, it needs to be abided by the Schedule M. Also, companies that make sterile products must follow the rules set by countries that buy them, such as the USFDA, EMA, WHO, and others.

As per different reports published recently, it has been observed that data Integrity has become one of the most important issues that is required to be resolved with immediate effect. Any problems with the integrity of the data can seriously put patient safety and product quality at risk. A strong framework for data control and regular checks are needed to find issues in data systems used for aspects like development, production, testing, marketing, and so on, they are also used for checking whether the overall operation is being done as per the law.

Manufacturing sterile injectables is very meticulous job and needs a lot of experience with aseptic handling. Contamination control, qualifying tools, managing utilities, parts quality, fill/finish processes, and visual inspection methods are all very important (Hout, 2021). GMP rules are required to be abided by while carrying out procedures like clean processes, proof methods, change control, errors, and correction actions.

Audits need to be done in areas like training, responsibility structures, NCR and CAPA management, change control, outsourcing processes, and management monitoring. It has also been observed that sustaining a careful attitude is a necessity for every employee while handling injectable sterile medicines. For injectable with high risks, strong systems are needed to keep an eye on harmful events, safety update reports must be sent on a regular basis, and risk management plans must be made. If the pharmaceutical organizations fail to abide by the above-mentioned rules, the patient can be vulnerable to different issues.

1.3 Research Aim and Objectives:

The aim of the research is to carefully look at and rate the compliance risks connected to making, quality control, data security, infrastructure, and the supply chain for injectable sterile pharmaceutical goods in India. This will allow us to suggest ways to lower those risks and make the process better.

Research objectives:

1. To examine the rules that govern injectable clean goods in India, setting the groundwork for comprehending the necessary compliance.
2. To locate and gather possible compliance risks connected with buildings, staff, quality control measures, and production methods for sterile injectable drugs.
3. To assess the potential impact of known compliance risks on the quality and safety of injectable products, including how bad they are and what they mean for public health.
4. To create effective risk-reduction plans by studying and rating compliance risks and suggesting best practices and process enhancements.
5. To support suggested risk-reduction strategies with real-life case studies from the Indian pharmaceutical industry, looking at examples of how compliance risks were handled well and the results of the strategies that were put in place.

1.4 Research Questions

1. What are the most important Indian rules and laws for sterile injectable products, and what are the most important conditions for following them?
2. What are the main places where sterile injectables compliance risks could arise in terms of buildings, staff, manufacturing methods, quality control, and data integrity?

3. How can the known compliance risks affect the quality, safety, effectiveness, and supply of the goods for patients if they are not dealt with? What amount of danger does each risk pose?
4. What strategies, solutions, controls, and best practices can be used to reduce the legal risks that have been identified? How can systems be made better so that compliance lasts?
5. What examples and case studies of good practices in India's compliance risk management for sterile injectables are available? What happened as a result of the tactics used in these situations?

1.5 Research Rationale

India makes a lot of generic injectable products. About 20% of all the drugs exported around the world come from India. But in the past few years, regulatory agencies like the US Food and Drug Administration (FDA) have been looking more closely at Indian facilities and taking more action against them for poor manufacturing practices, data security problems, and poor quality for sterile injectable products. This could be very bad for the health of the people and the safety of patients.

Concerns raised in recent warning letters and import reports sent to Indian companies that make injectable drugs include contaminated products, methods that haven't been properly validated, and tests and facilities that aren't up to par (Jain and Jain, 2021). During FDA checks, problems were found such as the growth of fungi in production areas, the failure to ensure sterility, and the absence of germ retention screens. These kinds of problems make it clear that quality culture and enforcement need more attention. Not following the regulations can also cause drug shortages if factories are not allowed to manufacture and send drugs to controlled markets. Also, problems with data integrity could lead officials to get wrong or confusing information during review, registration, and checks, which would make people question how reliable makers are.

Because of this, it is very important to look closely at the safety risks in India when manufacturing sterile injectables. Using a thorough risk-based approach to find problem areas lets people come up with focused solutions. These could include training staff, upgrading facilities, making data systems better, tweaking test methods, and so on. This will ensure long-term, reliable quality and output (Satheesh *et al.*, 2020). The researcher's goal is to come up with risk reduction and control methods that can be used right away. This way, makers will be able to manufacture generics of high quality while also meeting legal requirements. It will help the bigger goals of patient access, safety, and trust in public health. Another thing that will add

value is the focus on data integrity, supply chain control, and case studies from real life. Through evaluations of rules, production methods, quality culture, and known risks, the study aims to enhance cooperation in a planned way.

1.6 Research Limitations

One big problem with this compliance risk study is that it looks at a complicated business with lots of different rules. Since the study only looked at sterile injectable products, the results may not be applicable to other types of medicinal products. Also, limiting the reach to India is helpful for Indian companies, but it makes the system less useful around the world. The study uses information that is already out there, such as warning letters, government regulations, company papers, and secondary conversations or polls. It might be hard to get to makers' private or confidential internal data (Miglani *et al.*, 2022). This can make it harder to understand how things really work and what the quality culture is like. Making things, buildings, quality processes, and data are what's being looked at. But things like business goals, limited budgets, and the impact of people on compliance also matter but are not taken into account. Cost-benefit analysis will be used to make suggestions, but they might seem too good to be true because of real-world business problems.

1.7 Chapter Summary

The Indian pharmaceutical industry's role as a global provider of generic sterile injectables and the greater governmental scrutiny it has recently been subjected to regarding quality and compliance will be given in the first part. The chapter was instrumental in providing nuanced insights into the main aim and objectives of the research, and the questions that were answered were also identified. The main rationale for the conduction of the research was accompanied by the main significance that the outcome will have on the Indian pharmaceutical industry. The main obstacles that were observed during the conduction of the research were also explored in the chapter and will be aimed to be eradicated in future research.

2 Literature Review

2.1 Chapter Overview

This chapter will be aimed at exploration of a wide range of academic journals and articles that were focused upon figuring out the compliance risks for making sterile injectables. It will critically review the most important results, themes, and issues in the research. The main themes within the chapter will be developed based on the objectives that were set for the research. The gaps that were observed and noticed throughout the review of literature will also be demonstrated. The final subsection will be focused on the analysis and evaluation of the main discussion that will be carried out throughout the whole chapter

2.2 Regulatory Landscape Analysis

According to Singha and Mehtab (2020), the Drugs and Cosmetics Act, 1940 and Rules 1945 are the main laws that control how medicines are made, sold, and distributed in India. The Ministry of Health and Family Welfare's Central Drugs Standard Control Organisation (CDSCO) is in charge of enforcing these rules across the country. The Drugs and Cosmetics Act sets the rules for sterile injectable manufacturers on what they need to do to keep records, report harmful events, and fix quality problems. Biswal (2020) supported the argument and highlighted that the CDSCO standards also cover things like making sure processes abided by laws, incorporating technologies, managing quality risks, keeping data secure, and maintaining records. The authors also asserted that products that are sent abroad must also follow foreign rules such as WHO GMP and instructions from authorities like the US FDA, EMA, HC, and so on. The authors have observed different issues within this and identified them in detail. The authors observed that it is hard for CDSCO to do thorough and frequent checks because of limited resources. Seet *et al*., (2023) argued that in the past, there have also not been many steps taken against people who do not abide by the rules. But lately, global agencies have been looking more closely, especially when it comes to data integrity. As a result, CDSCO has taken steps to become more aligned with the international standards. With different third-party approvals, self-compliance is getting better with the progression of time. The authors also observed the strict rules that apply to sterile injectables in India and observed that the standards for compliance in areas like quality control, buildings, documentation, training, marketing, and so on are followed strictly and necessary actions are taken if any company does not abide by them. The main risks are being identified by the policymakers and necessary strategies are also recommended so that the laws are being abided by within the sector.

2.3 Identification of Compliance Risks

According to Kottapalli *et al.* (2023), sterile injectables are very sensitive products, and the ways they are manufactured and distributed pose big compliance risks. Not having strong process validation studies and reports can make it harder to show that industrial steps can be controlled and repeated. Higher contamination failure rates could happen if equipment approval, testing, maintenance, cleaning, and sterilization aren't taken care of properly. Lombardo *et al.*, (2022) supported the argument and asserted that environmental monitoring issues, improper maintenance of water and HVAC systems, and the chance of service failure can all make it more likely that the operations are not being carried out properly. Cross-contamination can happen when facilities are not designed well enough to separate processes, keep materials moving in only one way, have airlocks, and so on. Compliance can be hard to achieve if the system is old, not up to code, or the equipment doesn't meet the needs of Schedule Dabhi and Pandit (2024) explored that there are also risks when there are not enough trained staff with the right manufacturing skills within the companies. Ineffective sampling methods, lab investigations that don't follow the rules, and missing batch records for raw materials, packaging, intermediates, and bulk solutions can all lead to the release of flawed batches. If the microbial and chemical test methods and standards aren't right, contaminants might not be found, and this gap can also make sterile maintenance processes less effective.

According to Sawant *et al.* (2022), without strict vendor approval and supply chain openness and integrity controls, risks like changes in temperature, the entry of tampered or fake raw materials, and gaps in distribution documents are likely to happen. Quality can also be affected by breaks in the cold chain that happen while final goods are being stored and shipped.

Some data integrity risks that are very important to regulators include not keeping raw data records, changing logbooks, not integrating production and quality control systems properly, unauthorized data access, not reviewing the audit trail thoroughly enough, metadata that isn't relevant, and timestamp problems (Creelman *et al.*, 2022). Compliance risks also come from not having enough subject matter experts, not getting enough training on regulations, data governance principles, and technical topics, and not being able to create the quality culture and level of process discipline needed for sterile operations.

2.4 Assessment of Risk Impact

According to Ali Khan *et al.* (2021), the impact that not abiding by the laws has caused different risks to be aroused and thus the impact it has also becomes severe. Isolated cases of contamination have been reported even in developed markets because of failed equipment sterilization, high particulate matter, and bioburden that is not under control. This demonstrates

the overall severity of the risks within the market. Cross-contamination of products can happen directly when facilities aren't well designed or maintained, and thus the hygienic factors that are required to be maintained are not followed properly.

If tests and quality control aren't done properly, broken units may end up on the market causing the patients to be vulnerable to different hazards. The authors observed that sterility tests that didn't find fungal or microbial contaminants led to serious problems after they were given to patients in the past (Geyman and Settanni, 2020). The research further asserted that tampering with the raw materials can cause the quality of the drug to be degraded. It must also be observed that frequent changes in temperature along the supply chain can affect stability and render the product useless. The authors also noticed that breaks in the cold chain can make it hard for immune cells to recognize certain big molecules, and thus different issues may arise in terms of the functionality of the products.

As per Sundar *et al.* (2020), data leaks cause governmental trust to be hampered and the accuracy of the information that is sent also becomes less transparent. It can make it hard to get a detailed aspect of the tests and industrial controls that were used to make the product and get it ready for sale. Operator mistakes, batch failures, and not being able to quickly address differences or complaints happen when the employees within the production department do not provide full focus on maintaining quality standards. This changes the volume, quality, and supply of the goods. Therefore, the risks that have been found can affect the safety, purity, stability, effectiveness, and strength of injectable drugs in several ways. The authors argued that if these problems are not fixed with the right controls, they can cause patients to get sick or even cause death for the patients.

2.5 Development of Risk Mitigation Strategies

To raise the level of compliance and lower the risks to patient safety, strong risk reduction methods are needed in many areas. In addition to traditional process validation, there needs to be better process knowledge management, better sample methods, broad parametric release programs, and ongoing process verification (Lirio *et al.*, 2023). There needs to be more attention paid to cleanliness, user training, preventative maintenance, building and utility licensing, and the validation of important machines like sterilizers.

Integrated building design with one-way material flow, separate sterile areas, more automation, and controlled HVAC systems will make it easier to keep things clean. Upgrades to services and equipment must be made through regular qualification and capacity growth projects. The most important thing is to hire and keep trained staff. Quality control will be better with better analytical methods, standards, stability routines, checks on the integrity of container lids,

sample processes for raw materials and packaging parts, and records of analysis. Audits of the testing records and systems' data security, along with platform analysis tools, can make things more reliable (Salalli *et al.*, 2023). The supply chain will be safe thanks to strict vendor checks and contracts, tests of raw materials, and anti-counterfeit technologies such as blockchain, serialization, and forensic analysis. It is very important to have real-time tracking, redundant temperature controls, approved shippers, and qualified transportation partners.

A detailed data governance framework must be put in place across practical and quality tasks. This framework should include data life cycle management, roles and review, an audit trail, IT system validation, and analytics for early problem detection. Automated data gathering and analysis can open up new possibilities. Key for staff are customized GMP training programs, job change, e-learning courses, performance tests, and teaching on how to pass on knowledge about sterile production. Leadership must focus on a culture of quality with no defects, and everyone in the organization must be committed to following the rules. During the whole life cycle of a product, the goal of mitigation strategies is to set up strict controls that can reliably identify and limit any possible compliance breaches.

2.6 Validation through Case Studies

In 2018, the US Food and Drug Administration sent Sun Pharma a warning letter with 21 observations about data integrity at their Halol plant in Gujarat. The violations included changing sample run times and backdating records, not having the right access controls and audit trails, and not having enough data protection. This made it harder for Sun to follow the rules and ship to markets that are controlled. To solve this, Sun Pharma took a lot of corrective actions over two years, such as hiring a Global Head of Quality to manage all compliance efforts from one place. A framework for data integrity governance was set up (Panchal *et al.*, 2023). It included data lifecycle management, standard operating procedures for collecting and handling data, computer system validation, audit trail reviews, and role-based access limits. All workers were put through long training programmes on how to keep data safe. The company spent a lot of money to improve software and hardware in its labs and factories so that data could be captured automatically and mistakes in writing could be avoided.

By carefully putting in place strong data controls the way the US FDA wanted, the Sun Pharma Halol plant was able to fix all the problems and get back in line with the rules by 2020. It is shown in this case study that risks to data security can be reduced with strong management, clear rules, updated systems, and ongoing training. The US Food and Drug Administration (FDA) sent an import alert to Aurobindo's Unit XI plant in Telangana in 2018 because of problems with sterile assurance and cleanliness controls. This stopped the company from being

able to send sterile drugs to the US. It was found that the HVAC systems were not working properly, the number of non-viable particles was higher than expected, there were problems with validating the cleaning of equipment, and the standard operating procedures were not clear.

To address this, Aurobindo spent more than $30 million to improve the facilities and production lines in Unit XI. They changed the production flow so that parts could only move in one way between storage, preparation, mixing, filling, labelling, packing, and testing areas. The HVAC systems were made better, and automatic tracking was put in place. Important equipment for filling and sealing was updated to accommodate the newest technologies, and all parts that come into touch with the product were requalified. The amount of people working in places that needed to be kept clean was cut down, and tasks were automated where they could be. Controls for bacteria contaminants and extensive cleaning studies were put in place.

Because these big investments were made in infrastructure, equipment, automation, and process changes, Unit XI was able to fix all the problems by 2020 and get permission from the government to send sterile drugs to the US market again (Gonella *et al.*, 2022). This shows how important it is to improve infrastructure and production methods to lower the risks of manufacturing. In 2016, Dr Reddy's had problems with following the rules for distributing and keeping some of their shipped injection and biotech goods at the right temperature in the cold chain. During travel, these temperature-sensitive goods showed changes that went beyond the storage temperatures listed on the labels. This raised major questions about quality and effectiveness.

To lower these cold chain risks, Dr. Reddy's put GPS temperature trackers with monitors on all of their shipping cases so they could see changes in temperature in real-time. They set up predictive analytics software to find trends of risk along all of their transportation paths. The business spent money on better thermal packing options and extra chilled trucks and storage buildings. They also did a lot of research to make sure that all of their transportation companies were qualified to handle the cold chain.

2.7 Aseptic Processing and Sterilization Techniques

To make sterile medicines, things must be handled in an aseptic way. As part of it, people have to work in very controlled places with parts that have already been cleaned and sterilized. Aseptic processes often use laminar airflow areas, isolator systems, sterile lines and connections, tested cleaning methods, and workers who wear sterile protective gear. Cleanrooms are made to meet certain ISO standards for air cleaning so that they can be used for aseptic production (Makwana *et al.*, 2021). There are no loose fibres and they are easy to

clean. HEPA filters are used to control the amount of dust and dirt in the air and thus control over the airflow, temperature, and humidity are possible to be maintained. Every surface is regularly cleaned and germ-free and this causes the overall atmosphere to be hygienic. Some of the ways that reactors, hoppers, dryers, centrifuges, and other things are cleaned are by using steam-in-place, autoclaving, dry heat treatment, gamma irradiation, hydrogen peroxide gas, or chemicals. Standard operating procedures list the steps, stages, and requirements that must be met to get approval. The employment of steam traps and sterilized disconnections are done to keep the aseptic connectors clean and hygienic.

Everything that comes in contact with the product needs to be cleaned and sterilized before it is used (Khemariya, 2024). Capping is done immediately, and there are clean lines that go from one step to the next. Laser-based systems that sense particles can have issues, and these issues must be addressed properly.

Pre-sterilized components can be assembled to form complete packages with the help of terminal methods of sterilization such as compressed steam autoclaving, gamma irradiation, and ethylene oxide treatment. Constant vigilance of the aseptic process principally by means of media filling, airflow tracking, and personnel surveillance is extremely important. Well-planned apparatus, sterilized tools, standardized procedures, and continual training play significant roles in reducing the risks associated with sterile drug production. Hence these strategies should be included in the sector to improve the overall management of operation and effectiveness.

2.8 Cleanroom Design and Environmental Control

Cleanrooms are controlled settings that are meant to keep contamination to a minimum so that sterile products can be made. To get the level of air cleaning that is needed, cleanrooms are built and run in a certain way. The first step in designing a cleanroom is figuring out the right ISO classification based on the rules for the particles. Higher ISO classes let in fewer particles per unit of air. HVAC (heating, ventilation, and air conditioning) systems can be made to fit wind patterns, pressure differences, and the pattern of air circulation per hour once the classification is set. Cleanrooms use HEPA filters to get rid of contaminants in the air that are being moved. Usually, air comes in through the roof, goes through filters, and comes out near the floor. The impure air is being deprived from getting in through the maintenance of constant pressure. Keeping cleanrooms separate by pressure difference is another way to stop cross-contamination (Almeter *et al.*, 2022). Changing rooms with doors that lock into each other often have airlocks between cleanroom classes. Critical areas, like aseptic handling, have more

air changes than rooms nearby. Monitoring the environment is important to make sure that HVAC systems work right.



Figure 1: Schematic diagram of a cleanroom depicting how the clean air is supplied through HEPA filters and exhausted from the return grills (Graham et al., 2021)

The air quality is kept up by cleanroom clothes and cleaning procedures. Shedding is stopped by covering skin and hair. Gowning processes control what clothes can be worn. Sticky mats get dirt off of shoes. Surfaces and equipment are cleaned on a regular basis. The staff needs to be taught how to dress, move and be clean. High worker density raises the risk of contamination. Robotics can help cut down on the work that people have to do. Pass-through rooms or double-door entrances are used for material movement. Things like air returns, utility holes, stairs and dust catchers that were part of the building's plan are taken away. Smooth, non-porous surfaces with rounded sides make them easier to clean. To avoid damage, pipes, ducts, and wires are kept out of the clean area or marked off. Power, water, and compressed gasses are examples of backup services that keep things running smoothly. When process patterns change, HVAC balance needs to be done again. When materials are brought into cleanrooms, they need to be checked to make sure they don't release a lot of particles or toxic waste. Keeping cleanrooms in good shape takes constant work, testing, and improvement. Certification for working according to ISO 14644 is proof of quality (Graham *et al.*, 2021). To keep the particulate matter under control, people need to be very careful every day by counting air particles, keeping an eye on viables, checking pressure differences, and disinfecting regularly. Manufacturing sterile drugs in an aseptic way requires the strictest design, control, and maintenance of cleanrooms.

2.9 Batch Record Review and Documentation Control

Manufacturing information about each drug product batch is enclosed in batch production and control records. To make sure that accepted process methods and standards are being followed, batch records must be carefully looked over. Keeping accurate batch records is also a formal way to prove that something was made. Along with in-process controls and test results, batch production records should have step-by-step directions for how to do the work. It is important to keep track of equipment IDs, characteristics, run times, and programme versions. Operators write down the batch amounts, steps that have been finished, process data, outputs, and any differences that have been seen. Control records include the amounts of parts that were weighed or given out, how the equipment was set up, and the conditions of the surroundings.



Figure 2: Batch Records (Manik et al., 2023)

When a batch record is finished, it is looked over by both the quality and production units. The quality unit does the first check to make sure that the master batch records are followed (Manik *et al.*, 2023). Checks are made between important data points and copies of the raw data. It is proven that the steps that were carried out were consistent, correct, and full. Any differences or unusual findings are looked into to find out why they happened.

A second review is done by the production unit, which focuses on process flow, batch tracking, and technology ready for release. Before the batch is dispatched and the product is released, both reviews should take place. Reviewers need to have the right skills and know how to follow the process. Accessing electronic systems at the same time lets people do reviews at the same time. Reviewers make sure that the calculations are correct, that the equipment IDs match the logs, and all the necessary signs and dates are present, and all the changes are made in a controlled way. The strategy must be developed based on the level of risks that is being encountered. The risks must be analyzed properly, and finally suitable decisions are required

to be adopted and incorporated to make the review and control procedure successful and effective

Documentation methods must stop records from being wrong, missing, or impossible to read. According to CGMPs, data is entered at the same time by authorized people (Ma *et al.*, 2023). Simple writing without any judgment is what is intended. Data integrity is maintained by setting up audit trails in computer systems, reviewing these trails on a regular basis, making sure that records are created and stored correctly, controlling who can see records, teaching staff how to document properly, and regularly checking the quality of documentation processes. Good batch record forms and careful reviews improve the quality of sterile drug batches and inspectors' trust in them.

2.10 Personnel Training and Qualification Programs

It is one of the core necessities for all employees to be trained to manage jobs effectively. If an employee is facing an issue regarding any job within the company, conduction of training programs must be done for them to make them equipped with all necessary resources and knowledge that will make their efficiency higher. Procedures for everyday tasks (SOPs) are the major topic. The overall training procedures must be segregated into different steps, and this will allow the learning process to be steady and effective.

Professional training that is adapted as a person's job builds on basic training to give them more advanced skills. Tools in production are taught how to be cleaned, set up, used, fixed, maintained, and switched over. People who work in quality control learn how to test things, run labs, check for errors, and look into things (Krämer *et al.*, 2020). For people to keep and improve their skills, refresher training goes over both basic and advanced topics again. Usually, people need to take refresher training once a year. We may need to train people because of new tools, changes in the way things are done, or problems that keep happening. It's easier to give and keep track of training that includes films and other multimedia. Official rules say that workers must be able to do important jobs on their own before they are allowed to do them. They make sure that trainees can use what they have learned within the training programs and apply them to be more effective in the workplace. It says in the qualification rules what skills are needed, what kinds of results are acceptable, how to use linked SOPs, and what kinds of paperwork are needed. It's important to know how to use, clean, measure, keep, and fix tools with the right qualifications. Making sure that steps like setting up the tools, handling the ingredients, deciding on the working conditions, and getting samples done right are what process skills are for. The analytical skills test looks at how well people prepare standards and

chemicals, as well as how well people know how to set up instruments, examine data, and carry out analysis.

It is possible to get qualifications while being watched by trained instructors. The people in charge of quality and training look over the results and say they're good. The qualifications record has copies of written tests, observation logbooks, equipment logbooks, and other papers that back up the qualifications. If activities don't happen very often, people might need to be requalified.

A training database keeps track of when employees are trained and when they are qualified. There are records kept for each person that show the lessons they took and their grades. People look at records to see what training is needed, or records are shared between places to make sure that lessons are all the same (Nayak *et al.*, 2022). The teaching materials are always up-to-date, and professionals in the area have accepted them. Good training can lead to a well-educated staff, more work, and fewer mistakes. People learn basic things, get better at their jobs, change how they act, and the quality culture gets better. The authors observed that it is possible for a pharma company to abide by all the rules and regulations as per the standard benchmark when all the employees employed within the firm are well-trained in all aspects of ethical manufacturing and distribution.

2.11 Supplier Qualification and Management

Qualifying suppliers is important to make sure that the goods and services people buy meet high standards. With a risk-based method, more work is put into the most important providers. The first step is to find possible providers and have them fill out surveys about how they do business. When a supplier is first evaluated, their experience, past compliance, customer complaints, recalls, regulatory measures, and financial security are all looked at. Quality deals are made that spell out what is expected and who is responsible for what. Audits are done on high-risk sources to see how well they can make things and check the quality of their work. Suppliers are added to the list of accepted vendors once they have been approved (Nayak *et al.*, 2022). Ongoing tracking includes regular audits, reviews of COAs, checks to make sure the supply chain can be tracked, and talks about new problems that come up. If there are big changes, like new ownership, buildings, or methods, people need to requalify.

Quality control checks samples of bought goods and parts to see if they meet the requirements. The supplier's lot paperwork is looked over to make sure it meets standards and can be traced back to the source of the active ingredient. Specifications might need data on shared stability and scientific tests. The technology standards, change notice and termination rules, and terms of business are all spelt out in supply agreements. They give permission for quality systems,

subcontracting, and ways to handle complaints from suppliers. Specifications, sample processes, test methods, and COA/documentation outputs are all spelt out in technical agreements. Suppliers are required to give full supply chain tracking data, which includes the names of the manufacturer, secondary sites, packing operations, distribution networks, and locations. For handling tools, main packing, and important raw materials, sub-supplier requirements may be needed. A risk review of supplier-related processes looks at how different materials might affect the quality of the result. It describes the most important properties of the material, such as its stability, impurity transfer, and formulation similarity (Gonella *et al.*, 2022). Risk estimates for raw materials also look at how easy it is to get the materials and how complicated the process is.

Quality agreements for contract manufacturers spell out rules for following the law, how to handle changes, and the right to check. Audits check how well maintenance, testing, training, keeping batch records safe, and dealing with complaints work. Outsourcing deals spell out who is responsible for what, how to settle disagreements, and how to protect intellectual property. Performance tracking signs used by ongoing supplier management include complaints, rejections, quality fails, late or missing supplies, and response metrics. Trends lead to conversation and maybe even checks. As a result, action plans are made to deal with risks like quality problems or not having enough supplies (Makwana *et al.*, 2021). As a backup plan, qualified alternative providers could be found. To keep their accepted dealer standing, sellers must work hard and buyers must keep a close eye on them. A strong qualification system, along with performance tracking and relationship management, makes sure that the supply chain for making injectable products is reliable.

2.12 Research Gap

The review was detailed based on the main objectives of the research, but several limitations are required to be addressed. Some of the researches were focused on the aspect of data security and the main reason behind the compromising the security was also explored. However, the research lacked the exploration of in-depth strategies that will be useful for making the data secure. This must be done in the future research, and thus the review of literature will be more exploratory. Another gap is figuring out how likely and bad it is that people won't follow the rules. Previous research was mostly informal and didn't use statistics to look at risk factors. Making a mathematical risk model could help people identify and deal with problems better.

Most of the available material is about well-known international companies that do business in India. If people look at Indian companies with less experience in the aspect of risk, people might find different problems. It would also be interesting to look into the societal aspects of

quality and safety. Many studies highlight flaws that exist, but they don't give any real answers. It's time to turn risks into useful suggestions for Indian businesses (Almeter *et al.*, 2022). In the same way, there don't seem to be many cases of big non-compliances being fixed successfully in India that have been reported. Case studies from real life could motivate and direct growth. There is a lot of information about third-party control, but not as much on providers and contract makers. Because the business relies on complicated supply lines, threats linked to suppliers should also be looked at. Overall, a numeric, solution-focused risk analysis that is specific to Indian businesses, looks at a lot of compliance factors besides just GMPs, and highlights local success stories could fill in holes in knowledge and give industry players useful information.

2.13 Chapter Summary

The literature review brings together different studies that have been done on compliance risks for making Injectable drug products. These studies mostly looked at quality systems, controls for contamination, and data security. It looks at the results of scholarly studies, government reports, and papers that advise businesses. Controls for cleanrooms, aseptic processing, deviation management, staff training, material tracking, and IT systems are some of the most important topics that are looked at. The study shows that more research needs to be done on overall risk assessment, measuring effects, and giving Indian pharmaceutical companies specific answers.

3 Research Methodology

3.1 Chapter Overview

This will be regarded as the third chapter to be demonstrated within the research report, and the main factors that will be discussed in the chapter will be the research methods that were incorporated for the research. The approach and the philosophy are observed to be interlinked, and the justification for the selection of Positivism philosophy and deductive approach will be outlined. The data collection and the analysis technique will also be discussed, and the justification for the conduct of the survey and performing statistical analysis in SPSS will be verified and justified. The sampling method that was integrated into the research was also described. The research abided by all the ethical factors and the factors that were taken care of within the research will be provided.

3.2 Research Approach

The application of a deductive approach was done to find and rate compliance risks in injectable sterile products used in the Indian pharmaceutical industry. In this way, the researchers were able to employ established theories and guidelines about how to make sterile injectable products within the Indian Pharmaceutical sector abiding by all the legal requirements. The established theories were tested and finally validated through the final research outcome (Sawant *et al.*, 2022). The adoption of the approach also made the overall research to be abided by a logical structure. The adoption of the approach allowed the legal risks within the development of injectable sterile to be identified in a systematic manner. Comprehensive research was first done before any speculations or propositions were posted about the possible compliance risks that may arise in different aspects of making an injectable sterile. These aspects included layout of facility, the validation of equipment, the performance of process, quality control, employee training, data integrity and supply chain management. The validation of these aspects was done through several established theories, and the research facts already being inferred by other scholars.

The adoption of the research approach was also aligned with the type of data that were collected through surveys. The adoption of the approach allowed the quantitative data to be analyzed effectively and infer the outcome.

The objective of the research was to discover patterns, trends, and connections between the things that are thought to be risk factors and the real compliance issues or non-conformances seen in the Indian sterile injectable manufacturing business (Makwana *et al.*, 2021). These objectives were possible to be validated, and the inference of reliable outcomes allowed the analysis of the legal risks within the Indian Pharma industry regarding the injectable sterile

products. From the above discussion, it may be asserted that the incorporation of the deductive approach facilitated the final result to be inferred accurately.

3.3 Research Philosophy

The incorporation of a Positivism research philosophy was considered to be most appropriate for the research to assess the compliance risks regarding the manufacturing of injectable sterile within the Indian pharmaceutical industry. The adoption of the above mentioned philosophy allowed the research to be conducted through the application of facts rather than making assumptions. The adoption of the philosophy also allowed the researchers to not be biased. One of the core aspects of the positivism philosophy may be identified as the validation of the facts by testing established theories (Nikam *et al.,* 2023). The application of a survey was done to collect the data and was aligned with the positivism philosophy. The combination of all these allowed the assessment of the severity of the risks through the analysis of the statistical data collected through a survey.

The adoption of the research philosophy allowed the objectivity of the research to be sustained throughout the overall research process. The validity and the reliability of the result was also established effectively through the integration of the positivist research philosophy. Additionally, the objective way allowed the researchers to draw conclusions and infer assertions based on the real-world facts from the first study. Thus the adoption of the philosophy was justified for the research.

3.4 Data Collection Method

According to the research team, the data which was identified as the ideal data was quantitative, and they were collected through the conduction of a survey. The study aimed to track down and assess the compliance risks in injectable sterile products in the Indian pharmaceutical industry. A planned survey was a good way through which the responses from many workers employed in the Indian pharmaceutical industry could be collected. The process of the survey is to collect reactions that would be feasible to be represented using statistics, and, its main target was the coverage of the whole risk area within the Indian Pharmaceutical industry. The Likert-based close-ended questions were developed with the core issue of the research in mind and the responses were collected (Krämer *et al.,* 2020). The selection of 49 respondents associated with and employed within the Indian Pharmaceutical companies were selected for the survey process. The questionnaire was sent to the participants through their registered email addresses, and they were instructed to revert with the responses within 4 days.

A pilot survey was conducted using a small sample of respondents before the major survey to make sure that the survey tool was appropriate. If there are any flaws or missing elements in

question, they will locate these issues and unitize the required amendments throughout the assessments involved. The step helped the researchers to confidently affirm the data being collected and ensure it was correct and unbiased. The survey had a set of clearly worded instructions, an account of the study's aim and the confidentiality of the respondents who were to participate in the study was recognized (Isaacs *et al.,* 2023). The data that were collected were carefully sorted and set up for statistical analysis using the right tools and methods.

The quantitative survey method was successful in terms of providing data regarding how common, bad, and harmful compliance risks are in the Indian Pharmaceutical business for manufacturing sterile injectable products. The survey results, along with scientific evidence and data allowed me to come to a decision and put forward ideas for how to lower risks. Overall, the main survey method let the researchers get accurate data from a lot of different people. Thus the data collection method was appropriate for the research and allowed the outcome to be effective and aligned with the main objectives of the research.

3.5 Data Sampling

The sampling technique that was incorporated for the research was “Purposive Sampling”. The adoption of this sampling strategy allowed the bias of selecting employees to be eradicated and the respondents were selected within the specific industry. In total 49 participants employed within the Indian Pharmaceutical companies were selected for the research. The participants were selected based on how involved and informed they are in the Indian drug business, especially when it comes to following the rules and manufacturing sterile injectable products. Respondents were chosen based on things like their job tasks and roles in quality control, legal problems, how the plant works, and how well they follow the rules when manufacturing sterile injectable drugs. People with different amounts of experience were also a part of the group (Nayak *et al.,* 2022). They were experts with years of experience within the sector. There were participants from a lot of different Indian pharmaceutical companies there, from small to medium-sized businesses to large multinationals. Targeted searches were done on LinkedIn with the right words and filters to find possible participants.

As soon as participants were identified, they were sent individual offers and permission forms that explained the study's goals, protected their privacy, and asked them to freely take the survey. The invitation requests were sent to 70 participants, and the 49 participants who reverted were selected for the final survey process (Tavares *et al.,* 2020).

3.6 Data Analysis:

SPSS was used to analyze the collected data through a survey, and this allowed the data analysis to be effective. There will be a thorough approach, and the collected data will be used in several

scientific ways to find useful information. To start, summary data was used to bring together and make sense of the survey results. Analysis of the data was made with frequencies, percentages, means, and standard deviations. These allowed the researchers to find the main trends and patterns regarding the main objectives of the research and the data. The researchers employed correlation analysis to evaluate how the different factors are interconnected. This allowed the researchers to find out how strong and which way the connections are between possible risk factors, compliance problems, and how people think these aspects affect the quality, safety, and supply of a product (Dmour, 2023). The compliance risks that have been found were also tested against some factors to assess their overall reliability. With this method, the researcher was able to explore important parameters and make models that can predict what will happen.

ANOVA and t-tests were also integrated to see if there are significant changes in how people think about or act on compliance risk based on things like the size of the company, its location, or the authority in charge of regulations. The reliability of the survey instrument was assessed using tools such as Cronbach's Alpha to make sure it functions consistently every time (Ren and Hussein, 2021). While conducting the study, the author also mentioned different types of mistakes, missing data and failures to comply with common statistical rules. Various instruments like regression and robust statistical methods in dealing with these problems always insured that the data were correct and dependable... The application of charts, graphs were done to visualize the research outcome effectively. The researchers incorporated strict statistical methods to look at the data, and the final outcome was significant in terms of fulfilling the objectives of the research.

3.7 Validity and Reliability

Accurate and reliable steps were incorporated to make sure the study results were correct before they were finalized. An important aspect to look for in a study tool was how often and regularly it works. Links and failure tests were used to be sure of the reliability of the final outcome. Correlation analysis was used to find links between different parameters. The application of regression analysis was also done to check how well various factors can forecast the discovered compliance risks. This helped the researchers to show that the models and ideas from the study are real. The application of the Cronbach's alpha tool was done to assess the reliability of the survey tool.

Along with surveys, different expert opinions were used to make the research tool even more reliable and real. The research employed strict statistical methods to look at the data, and the results were inferred with respect the research’s goals and the problems that only the Indian

pharmacy business faces. Through the application of these measures, the research was successful in determining the validity and the reliability of the final result effectively.

3.8 Ethical Considerations

If the researcher wants to study, ethics should be the first thought. Abiding by several ethical factors allows the effectiveness of any research to be improved and enhanced. This is especially true when the researcher is working with private data and people as clients. It looks for and rates compliance risks in sterile injectable products in the Indian pharmaceutical business (Ramani et al., 2021). This study will also look at some moral issues. At first, the idea of "informed consent" will be taken very seriously. That everyone who wants to take part will be fully informed about the study's goals, how they can participate, and how the data will be used. They can join on their own, without being pushed or swayed once they know about it. People who take part will be asked to agree in writing or online before any data is collected. The research was free from the data being falsified and fabrication of data was also avoided.

To protect privacy and keep things secret, there will be strict rules during the whole study. Certain safety steps will be put in place to make sure that any data collected from employees stays private and can't be used to track down specific people. Any data that could be used to find the researcher will be taken away or kept safe, so they can't be found. The information will be handled and kept safe so that only professionals who are allowed to see it can see it. Institutional review boards (IRBs) or ethics groups will have set moral standards and rules for the study. Please follow them. As soon as the data collection starts, rights and permissions will be checked. We can be sure that the study is good and that the people being observed are cared for (Bushra and Tabassum, 2020). Everything will be carefully thought out. A survey and other ways to get information are meant to be easy for the people who fill them out and not worry, stress, or make their lives harder. The data that were collected from the participants were stored with string encryption measures, and they will be destroyed permanently after the receiving of grades.

The study results will also be shared clearly and honestly, with no lies or biased details. There will be no illegal or hidden effects once the findings are made public. The people or groups taking part in the study will feel respected if these moral rules are followed. This will also keep the study honest, help us learn more, and keep the risks to a minimum.

3.9 Chapter Summary

The main focus of the chapter was on the analysis and evaluation of the research methods that were incorporated into the research. A detailed evaluation of the approach and the philosophy was provided and the main reasons for the adoption were also identified. It was planned that

49 people from Indian pharmaceutical companies would be a part of the data sampling. The researcher employed SPSS software to do descriptive statistics, association, regression, and reliability tests, among other types of statistical analysis. To check for reliability, the researcher employed Cronbach's alpha. To check for validity, the researcher applied correlation and regression studies. To keep the study method honest, things like getting full approval, keeping information private, and all the rules will be followed properly.

4 Findings and Analysis

4.1 Chapter Overview

The results section shows all the survey data that was gathered to examine and rate the compliance risks in the manufacturing of sterile products within the Indian pharmaceutical industry. The study questions and goals are laid out in an outline at the beginning, which sets the stage for what follows. The chapter describes different topics, such as the participants who answered the survey, how they felt about regulatory frameworks, how sure they were that they could maintain sterile injectables, how important it was to train staff, how useful quality control measures were, data security protocols, infrastructure design, and ways to lower risks. Data such as frequency charts, mean scores, and standard deviations, were used to show the most important findings. To establish links between the data obtained and the research objectives set out in the thesis, inferential statistics such as regression analyses and correlation studies were also used.

4.2 Results

Frequency Tables

Table 1: Frequency Table representing Age (Source: SPSS)

What is Your Age?					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Under 25 years old	4	8.2	8.2	8.2
	25-34 years old	13	26.5	26.5	34.7
	35-44 years old	13	26.5	26.5	61.2
	45-54 years old	16	32.7	32.7	93.9
	55 years old and above	3	6.1	6.1	100.0
	Total	49	100.0	100.0	



Figure 3: Bar Chart for Age (Created in Microsoft Excel)

The above figure is used to demonstrate the graph demonstrating age of the respondents who took part in the survey. The X-axis is used to represent the age category and the Y-axis is used to represent the number of participants.

Table 2: Frequency Table representing Educational Qualification (Source: SPSS)

What is Your Educational Qualification?					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	High School or equivalent	3	6.1	6.1	6.1
	Bachelor's degree	8	16.3	16.3	22.4
	Master's degree	21	42.9	42.9	65.3
	Doctorate or professional degree	10	20.4	20.4	85.7
	Vocational/Technical training	7	14.3	14.3	100.0
	Total	49	100.0	100.0	



Figure 4: Bar Chart for Educational Qualification (Created in Microsoft Excel)

The above figure is used to illustrate the educational qualification of the respondents who took part in the survey. The X-axis is used to represent the list of educational qualifications and the Y-axis is used to represent the Number of participants.

Table 3: Frequency Table representing Occupation (Source: SPSS)

What is Your Occupation?					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Pharmaceutical industry professional	22	44.9	44.9	44.9
	Healthcare practitioner (doctor, nurse, pharmacist, etc.)	5	10.2	10.2	55.1
	Regulatory agency employee	10	20.4	20.4	75.5
	Academic researcher or educator	12	24.5	24.5	100.0
	Total	49	100.0	100.0	



Figure 5: Bar Chart for Occupation (Created in Microsoft Excel)

The figure above is used to demonstrate the occupation for all the respondents who took part in the survey. The X-axis is used to represent different categories of occupation and the Y-axis is used to represent the number of participants.

Table 4: Frequency Table representing Years of Experience (Source: SPSS)

How many years of experience do you have working in the sterile pharmaceutical manufacturing industry?					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	More than 5 years of experience	29	59.2	59.2	59.2
	Less than 5 years of experience	18	36.7	36.7	95.9
	No experience	2	4.1	4.1	100.0
	Total	49	100.0	100.0	



Figure 6: Bar Chart for Years of Experience (Created in Microsoft Excel)

The figure above is used to visualize the Years of experience possessed by the respondents who took part in the survey. The X-axis is used to represent three segments of the years of experience and the Y-axis is used to represent the number of participants.

Table 5: Table for current regulatory framework governing sterile injectable pharmaceutical production. (Source: SPSS)

The current regulatory framework governing sterile injectable pharmaceutical production in India is adequate to ensure compliance with quality standards.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	3	6.1	6.1	6.1
	Disagree	3	6.1	6.1	12.2
	Neither Agree nor Disagree	8	16.3	16.3	28.6
	Agree	21	42.9	42.9	71.4
	Strongly Agree	14	28.6	28.6	100.0
	Total	49	100.0	100.0	



Figure 7: Bar Chart for Research Based Question 1 (Created in Microsoft Excel)

The figure above is used to represent the opinions of the respondents regarding the current regulatory framework governing sterile injectable pharmaceutical production in India. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 6: Table for the ability of pharmaceutical facilities in India to maintain sterile conditions. (Source: SPSS)

I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	4	8.2	8.2	8.2
	Disagree	3	6.1	6.1	14.3
	Neither Agree nor Disagree	8	16.3	16.3	30.6
	Agree	14	28.6	28.6	59.2
	Strongly Agree	20	40.8	40.8	100.0
	Total	49	100.0	100.0	



Figure 8: Bar Chart for Research-Based Question 2 (Created in Microsoft Excel)

The figure above is used to represent the opinions of the respondents regarding their confidence on the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 7: Table for sufficient emphasis on staff training and education regarding compliance with sterile injectable production regulations. (Source: SPSS)

There is sufficient emphasis on staff training and education regarding compliance with sterile injectable production regulations in Indian pharmaceutical facilities.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	6	12.2	12.2	12.2
	Disagree	2	4.1	4.1	16.3
	Neither Agree nor Disagree	10	20.4	20.4	36.7
	Agree	13	26.5	26.5	63.3
	Strongly Agree	18	36.7	36.7	100.0
	Total	49	100.0	100.0	



Figure 9: Bar Chart for Research-Based Question 3 (Created in Microsoft Excel)

The figure above is used to represent the opinions of the respondents regarding the sufficient emphasis on staff training and education regarding compliance with sterile injectable production regulations in Indian pharmaceutical facilities. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 8: Table for Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks. (Source: SPSS)

Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	1	2.0	2.0	2.0
	Disagree	5	10.2	10.2	12.2
	Neither Agree nor Disagree	7	14.3	14.3	26.5
	Agree	21	42.9	42.9	69.4
	Strongly Agree	15	30.6	30.6	100.0
	Total	49	100.0	100.0	



Figure 10: Bar Chart for Research-Based Question 4 (Created in Microsoft Excel)

The figure above is used to represent the opinions of the respondents regarding the quality control measures implemented in Indian pharmaceutical facilities to effectively identify and mitigate risks associated with sterile injectable production. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 9: Table for Data security protocols in place within Indian pharmaceutical companies (Source: SPSS)

Data security protocols in place within Indian pharmaceutical companies adequately safeguard sensitive information related to sterile injectable production.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	3	6.1	6.1	6.1
	Disagree	2	4.1	4.1	10.2
	Neither Agree nor Disagree	7	14.3	14.3	24.5
	Agree	18	36.7	36.7	61.2
	Strongly Agree	19	38.8	38.8	100.0
	Total	49	100.0	100.0	



Figure 11: Bar Chart for Research-Based Question 5 (Created in Microsoft Excel)

The figure above is used to represent the opinions of the respondents regarding the data security protocols integrated within Indian pharmaceutical companies to safeguard sensitive information related to sterile injectable production. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 10: Table for Infrastructure within Indian pharmaceutical facilities is appropriately designed to support the production of sterile injectable medications. (Source: SPSS)

Infrastructure within Indian pharmaceutical facilities is appropriately designed to support the production of sterile injectable medications.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	2	4.1	4.1	4.1
	Disagree	6	12.2	12.2	16.3
	Neither Agree nor Disagree	2	4.1	4.1	20.4
	Agree	14	28.6	28.6	49.0
	Strongly Agree	25	51.0	51.0	100.0
	Total	49	100.0	100.0	



Figure 12: Bar Chart for Research-Based Question 6 (Created in Microsoft Excel)

The figure above is used to represent the viewpoints of the participants regarding the infrastructure within Indian pharmaceutical facilities to appropriately design and support the production of sterile injectable medications. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 11: Table for Non-compliance with regulations governing sterile injectable production. (Source: SPSS)

Non-compliance with regulations governing sterile injectable production poses a significant risk to the quality and safety of pharmaceutical products in India.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	1	2.0	2.0	2.0
	Disagree	2	4.1	4.1	6.1
	Neither Agree nor Disagree	7	14.3	14.3	20.4
	Agree	16	32.7	32.7	53.1
	Strongly Agree	23	46.9	46.9	100.0
	Total	49	100.0	100.0	



Figure 13: Bar Chart for Research-Based Question 7 (Created in Microsoft Excel)

The figure above is used to represent the viewpoints of the participants regarding the significant risk to the quality and safety of pharmaceutical products due to non-compliance with regulations governing sterile injectable production. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 12: Table for implementing effective risk-reduction strategies. (Source: SPSS)

Implementing effective risk-reduction strategies can significantly improve compliance with sterile injectable production regulations in Indian pharmaceutical facilities.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Disagree	1	2.0	2.0	2.0
	Neither Agree nor Disagree	8	16.3	16.3	18.4
	Agree	12	24.5	24.5	42.9
	Strongly Agree	28	57.1	57.1	100.0
	Total	49	100.0	100.0	



Figure 14: Bar Chart for Research-Based Question 9 (Created in Microsoft Excel)

The figure above is used to represent the viewpoints of the participants regarding the implementation of effective risk-reduction strategies to significantly improve compliance with sterile injectable production regulations in Indian pharmaceutical facilities. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 13: Table for continuous improvement initiatives are essential for maintaining compliance with sterile injectable production regulations. (Source: SPSS)

Continuous improvement initiatives are essential for maintaining compliance with sterile injectable production regulations in Indian pharmaceutical facilities.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	3	6.1	6.1	6.1
	Disagree	3	6.1	6.1	12.2
	Neither Agree nor Disagree	4	8.2	8.2	20.4
	Agree	12	24.5	24.5	44.9
	Strongly Agree	27	55.1	55.1	100.0
	Total	49	100.0	100.0	



Figure 15: Bar Chart for Research-Based Question 9 (Created in Microsoft Excel)

The figure above is used to represent the viewpoints of the participants regarding the necessity for continuous improvement initiatives for maintaining compliance with sterile injectable production regulations in Indian pharmaceutical facilities. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Table 14: Table for the role of case studies in terms of recommending future strategies. (Source: SPSS)

Case studies and examples of successful compliance management practices within the Indian pharmaceutical industry are valuable for informing future strategies.					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Strongly Disagree	2	4.1	4.1	4.1
	Disagree	3	6.1	6.1	10.2
	Neither Agree nor Disagree	4	8.2	8.2	18.4
	Agree	12	24.5	24.5	42.9
	Strongly Agree	28	57.1	57.1	100.0
	Total	49	100.0	100.0	



Figure 16: Bar Chart for Research-Based Question 10 (Created in Microsoft Excel)

The figure above is used to represent the viewpoints of the participants regarding the usefulness of the case study for informing future strategies for successful management practices. The X-axis is used to represent the Likert Scale responses list and the Y-axis is used to represent the number of participants.

Reliability Test (Alpha Model)

The high level of internal consistency across the survey items is supported by Cronbach's alpha score of 0.759. The questions assess several facets of regard and opinion. How individuals felt about the several processes in making sterile items is shown by the numbers on the scale, which range from 1.4490 to 4.3673. It reveals a wide variety of viewpoints on a variety of topics, with values ranging from 0.57956 to 1.33853. With 49 respondents per question, the survey instrument effectively gauges public opinion on compliance risks and procedures within the Indian pharmaceutical industry.

Table 15: Table for Reliability statistics

Reliability Statistics	
Cronbach's Alpha	No of Items
.759	14

Table 16:Table for Item Statistics			
	Mean	**Std. Deviation**	**N**
What is Your Age?	3.0204	1.08953	49
What is Your Educational Qualification?	3.2041	1.07973	49
What is Your Occupation?	2.2449	1.26706	49
How many years of experience do you have working in the sterile pharmaceutical manufacturing industry?	1.4490	.57956	49
The current regulatory framework governing sterile injectable pharmaceutical production in India is adequate to ensure compliance with quality standards.	3.8163	1.11193	49
I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications.	3.8776	1.25221	49
There is sufficient emphasis on staff training and education regarding compliance with sterile injectable production regulations in Indian pharmaceutical facilities.	3.7143	1.33853	49
Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production.	3.8980	1.02561	49

Data security protocols in place within Indian pharmaceutical companies adequately safeguard sensitive information related to sterile injectable production.	3.9796	1.12712	49
Infrastructure within Indian pharmaceutical facilities is appropriately designed to support the production of sterile injectable medications.	4.1020	1.19452	49
Non-compliance with regulations governing sterile injectable production poses a significant risk to the quality and safety of pharmaceutical products in India.	4.1837	.97197	49
Implementing effective risk-reduction strategies can significantly improve compliance with sterile injectable production regulations in Indian pharmaceutical facilities.	4.3673	.83401	49
Continuous improvement initiatives are essential for maintaining compliance with sterile injectable production regulations in Indian pharmaceutical facilities.	4.1633	1.19630	49
Case studies and examples of successful compliance management practices within the Indian pharmaceutical industry are valuable for informing future strategies.	4.2449	1.10925	49

Table 17: Table for Scale Statistics

Scale Statistics			
Mean	Variance	Std. Deviation	N of Items
50.2653	57.407	7.57676	14

As shown by the Cronbach's alpha score of 0.759, the survey questions are very consistent with each other. The questions measure different aspects of respect and views. The numbers from 1.4490 to 4.3673 on the scale show how people felt about the various steps involved in manufacturing sterile products. It ranges from 0.57956 to 1.33853, and it shows how different people's opinions are for various things. With 49 people responding to each question, the survey tool does a good job of finding out what people think about compliance risks and practices in the Indian pharma business.

Table 18: Table for Regression Analysis between Quality Control Measures and Compliance Emphasis

Regression Analysis between Quality Control Measures and Compliance Emphasis					
Source	Sum of Squares	df	Mean Square	F	Sig.
Regression	36.743	4	9.186	8.205	.000
Residual	49.257	44	1.119		
Total	86.000	48			

a. Dependent Variable: There is sufficient emphasis on staff training and education regarding with sterile injectable production regulations in Indian pharmaceutical facilities.

b. Model: In Indian pharmaceutical enterprises producing sterile injectables, quality control methods include strict testing procedures, environmental monitoring, staff training, and adherence to international requirements. By efficiently recognizing and reducing contamination hazards, these steps guarantee the effectiveness and security of the injected goods.

The regression analysis shows a significant relationship between staff training on compliance and quality control measures in Indian pharmaceutical facilities regarding sterile injectable production regulations ($F(4, 44) = 8.205$, $p < .000$). The model explains a substantial portion of the variance ($R^2 = 0.427$) in identifying and mitigating production risks.

Table 19:Bayesian Estimates of Coefficientsa,b,c					
Parameter	Posterior			95% Credible Interval	
	Mode	Mean	Variance	Lower Bound	Upper Bound
(Intercept)	4.067	4.067	.078	3.516	4.617
Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production. = Strongly Disagree	-.067	-.067	1.251	-2.269	2.136
Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production. = Disagree	-2.867	-2.867	.313	-3.968	-1.766
Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production. = Neither Agree nor Disagree	-.495	-.495	.246	-1.471	.481
Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production. = Agree	.029	.029	.134	-.692	.749

Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production. = Strongly Agree	.[d]	.[d]	.[d]	.[d]	.[d]

a. Dependent Variable: There is sufficient emphasis on staff training and education regarding compliance with sterile injectable production regulations in Indian pharmaceutical facilities.

b. Model: (Intercept), Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production.

c. Assume standard reference priors.

d. This parameter is redundant. Posterior statistics are not calculated.

Table 20: Table for Bayesian Estimates of Error Variance

Bayesian Estimates of Error Variance[a]					
Parameter	Posterior			95% Credible Interval	
	Mode	Mean	Variance	Lower Bound	Upper Bound
Error variance	1.071	1.173	.069	.767	1.786

a. Assume standard reference priors.

Table 21: Table for Regression Between the current regulatory framework and Maintenance Regression

Regression Between the current regulatory framework and Maintenance Regression					
Source	Sum of Squares	df	Mean Square	F	Sig.
Regression	19.541	4	4.885	5.400	.001
Residual	39.806	44	.905		
Total	59.347	48			

a. Dependent Variable: The current regulatory framework governing sterile injectable pharmaceutical production in India is adequate to ensure compliance with quality standards.

b. Model: (Intercept), I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications.

Table 22: Table for Bayesian Estimates of Coefficientsa,b,c					
Parameter	Posterior			95% Credible Interval	
	Mode	Mean	Variance	Lower Bound	Upper Bound
(Intercept)	4.400	4.400	.047	3.971	4.829
I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications. = Strongly Disagree	-1.650	-1.650	.284	-2.700	-.600
I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications. = Disagree	-2.067	-2.067	.363	-3.254	-.880
I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications. = Neither Agree nor Disagree	-1.025	-1.025	.166	-1.827	-.223
I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications. = Agree	-.543	-.543	.115	-1.211	.125

I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications. = Strongly Agree	.[d]	.[d]	.[d]	.[d]	.[d]

a. Dependent Variable: The current regulatory framework governing sterile injectable pharmaceutical production in India is adequate to ensure compliance with quality standards.

b. Model: (Intercept), I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications.

c. Assume standard reference priors.

d. This parameter is redundant. Posterior statistics are not calculated.

Table 23:Bayesian Estimates of Error Variance

Bayesian Estimates of Error Variance[a]					
Parameter	Posterior			95% Credible Interval	
	Mode	Mean	Variance	Lower Bound	Upper Bound
Error variance	.865	.948	.045	.620	1.444

a. Assume standard reference priors.

Correlations among variables

The correlation analysis reveals significant relationships among variables. Age has no significant correlation with other factors. Educational qualification correlates moderately with occupation ($r = .191$, $p = .188$) and years of industry experience ($r = .283$, $p = .049$). Occupation correlates positively with experience ($r = .358$, $p = .012$). Confidence in sterile conditions correlates positively with regulatory adequacy ($r = .552$, $p < .001$) and industry confidence ($r = .552$, $p < .001$)

Table 24: Corelations among variables														
What is Your Age?	Sig. (2-tailed)		.000	.223	.208	.542	.473	.791	.161	.906	.654	.142	.598	.841
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
What is Your Educational Qualification?	Pearson Correlation	.528**	1	.191	.283*	.171	.173	-.031	-.112	.260	.113	.241	.031	-.026
	Sig. (2-tailed)	.000		.188	.049	.241	.235	.833	.442	.071	.441	.095	.834	.857
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
What is Your Occupation?	Pearson Correlation	.177	.191	1	.358*	-.234	-.204	-.130	-.077	-.040	-.017	-.054	-.245	-.054
	Sig. (2-tailed)	.223	.188		.012	.106	.160	.374	.601	.784	.908	.711	.090	.710
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
How many years of experience do you have working in the sterile pharmaceutical manufacturing industry?	Pearson Correlation	.183	.283*	.358*	1	.066	.049	-.153	-.062	-.113	-.128	.109	-.090	.072
	Sig. (2-tailed)	.208	.049	.012		.652	.740	.292	.675	.438	.382	.454	.540	.621
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
The current regulatory framework governing sterile injectable	Pearson Correlation	.089	.171	-.234	.066	1	.552**	.398**	.422**	.379**	.093	.398**	.456**	.368**

pharmaceutical production in India is adequate to ensure compliance with quality standards.	Sig. (2-tailed)	.542	.241	.106	.652		.000	.005	.003	.007	.526	.005	.001	.009
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
I am confident in the ability of pharmaceutical facilities in India to maintain sterile conditions during the production of injectable medications.	Pearson Correlation	-.105	.173	-.204	.049	.552**	1	.339*	.282*	.471**	.245	.395**	.303*	.320*
	Sig. (2-tailed)	.473	.235	.160	.740	.000		.017	.050	.001	.089	.005	.034	.025
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
There is sufficient emphasis on staff training and education regarding compliance with sterile injectable production regulations in Indian pharmaceutical facilities.	Pearson Correlation	-.039	-.031	-.130	-.153	.398**	.339*	1	.464**	.673**	.370**	.329*	.245	.173
	Sig. (2-tailed)	.791	.833	.374	.292	.005	.017		.001	.000	.009	.021	.089	.235

	N	49	49	49	49	49	49	49	49	49	49	49	49	49
Quality control measures implemented in Indian pharmaceutical facilities effectively identify and mitigate risks associated with sterile injectable production.	Pearson Correlation	-.203	-.112	-.077	-.062	.422**	.282*	.464**	1	.395**	.315*	.291*	.459**	.336*
	Sig. (2-tailed)	.161	.442	.601	.675	.003	.050	.001		.005	.028	.043	.001	.018
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
Data security protocols in place within Indian pharmaceutical companies adequately safeguard sensitive information related to sterile injectable production.	Pearson Correlation	.017	.260	-.040	-.113	.379**	.471**	.673**	.395**	1	.497**	.346*	.208	.281
	Sig. (2-tailed)	.906	.071	.784	.438	.007	.001	.000	.005		.000	.015	.152	.051
	N	49	49	49	49	49	49	49	49	49	49	49	49	49

Infrastructure within Indian pharmaceutical facilities is appropriately designed to support the production of sterile injectable medications.	Pearson Correlation	-.066	.113	-.017	-.128	.093	.245	.370**	.315*	.497**	1	.324*	.213	.498**
	Sig. (2-tailed)	.654	.441	.908	.382	.526	.089	.009	.028	.000		.023	.143	.000
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
Non-compliance with regulations governing sterile injectable production poses a significant risk to the quality and safety of pharmaceutical products in India.	Pearson Correlation	.213	.241	-.054	.109	.398**	.395**	.329*	.291*	.346*	.324*	1	.455**	.386**
	Sig. (2-tailed)	.142	.095	.711	.454	.005	.005	.021	.043	.015	.023		.001	.006
	N	49	49	49	49	49	49	49	49	49	49	49	49	49

Implementing effective risk-reduction strategies can significantly improve compliance with sterile injectable production regulations in Indian pharmaceutical facilities.	Pearson Correlation	-.077	.031	-.245	-.090	.456**	.303*	.245	.459**	.208	.213	.455**	1	.461**
	Sig. (2-tailed)	.598	.834	.090	.540	.001	.034	.089	.001	.152	.143	.001		.001
	N	49	49	49	49	49	49	49	49	49	49	49	49	49
Continuous improvement initiatives are essential for maintaining compliance with sterile injectable production regulations in Indian pharmaceutical facilities.	Pearson Correlation	.029	-.026	-.054	.072	.368**	.320*	.173	.336*	.281	.498**	.386**	.461**	1
	Sig. (2-tailed)	.841	.857	.710	.621	.009	.025	.235	.018	.051	.000	.006	.001	
	N	49	49	49	49	49	49	49	49	49	49	49	49	49

Case studies and examples of successful compliance management practices within the Indian pharmaceutical industry are valuable for informing future strategies.	Pearson Correlation	-.021	.027	-.132	.052	.291*	.247	.315*	.389**	.254	.295*	.460**	.148	.158
	Sig. (2-tailed)	.884	.854	.364	.721	.043	.087	.028	.006	.078	.039	.001	.309	.279
	N	49	49	49	49	49	49	49	49	49	49	49	49	49”

4.3 Discussion

Regulatory Framework Perception

The results show that people have various thoughts on how the Indian regulations for manufacturing of sterile products. Many of the people who answered said they were sure of the current regulatory system, but many also said they were worried or didn't see anything wrong with it. People who like how the government controls things probably like the rules organizations like the Central Drugs Standard Control Organization (CDSCO) make. The role of these groups is to make sure that medicines are safe, efficacy, and of high quality. These regulations might make them think that they cover everything and are good at getting people to follow them.

People who say they have questions, on the other hand, might point out places where they think the government is missing or not good enough. People may be worried because they see problems with following the regulatory laws, have different ideas about what it means, or think that global standards will change faster than the laws that are in place now. The different views on the system of government show how hard it is to make sure that the drug business meets the regulations. Everyone needs to talk about these different points of view if they want to work together to make the government more responsible and build trust in the safety and quality of Indian sterile drug products.

Confidence in Sterile Conditions Maintenance

The survey found that most of the people who answered were positive about India's pharmaceutical plants' ability to maintain sterility while manufacturing drugs for injections. One can tell that people trust the business to be clean because most of them said they were sure or very confident in this area. One reason for this trust is that drug companies take a lot of care to follow Good Manufacturing Practices (GMP) and other government rules. There are strict rules about how to clean and sterilize things, manage settings, and always keep an eye on the air quality and particulate matter in cleanrooms.

It is interesting, though, that some of the people who answered had questions or were not sure how to keep things clean. There may be worry behind these reactions because of the few mistakes or cases of survey that have been mentioned in the business. When drug companies deal with these problems, they should do so in a clear and effective way that shows they are committed to quality and best practices. Overall, most of the people who answered are sure they maintain sterile conditions required for manufacturing. But the fact that people have

different thoughts shows how important it is to keep an eye on things and make sure they are quality all the way through the process of making a medicine.

Emphasis on Staff Training and Education

The regression and correlation analysis show how quality control measures are related to the focus on staff training and education to make sure they follow the rules for making sterile injectables in Indian pharmaceutical plants. Based on the regression analysis, there is a statistically significant link between these factors. This means that as quality control measures get better, staff training and education tend to get more attention. This study shows how important it is to put money into training staff to improve compliance and lower the risks that come with manufacture of sterile products.

The association study also shows that there are moderately good links between staff training and education focus and a number of other important factors, such as trust in maintaining sterile conditions and the efficiency of quality control methods. This means that companies that put a high priority on training and education for their employees are likely to have more faith in their production processes and be better at finding and reducing risks. Overall, these results show how important it is for staff to keep learning and improving their skills in order to make sure that high quality and safety standards are met when manufacturing sterile injectable products. Putting money into training programmes and encouraging a mindset of learning can help the pharmaceutical business cut down on risk and improve total operating quality.

Effectiveness of Quality Control Measures

Different factors that affect whether Indian drug factories follow the rules for making sterile injectables are linked to how well quality control measures work, as shown by the regression and correlation studies. Another important finding from the regression analysis is that there is a link between other things and how well quality control methods work. It seems that better quality control is linked to better attempts to follow the rules. This finding shows how important it is to have good quality control methods to make sure that sterile injectable drugs are safe and efficient.

The association study also found strong positive links between how well quality control measures are put in place and important things like trust in maintaining sterility and how well the infrastructure is designed. In other words, factories that have better quality control measures are more likely to trust their production methods and have better-designed tools to help them manufacture sterile injectables. It's clear from these data that quality control is very important for making sure that rules are followed and that safety and quality standards are kept high.

Pharma industries should always look at and improve their quality control measures to make sure they follow the rules and keep risks to the lowest level for manufacturing sterile injectables.

Data Security Protocols

The information about how Indian drug firms protect their data tells us a lot about the steps they take to keep private data about making safe clean injectables. Most of the people who answered are sure that the steps taken to protect data are enough, and a lot of them are very sure that they work. This is likely because people in the business know how important it is to keep things like product recipes, manufacturing methods, and quality control data hidden. It's important to note, though, that some respondents aren't sure about data security processes or have questions about them. Some people may have these views because they are worried about weak spots in the current systems, possible breaches, or the fact that the online threats the pharmaceutical industry sees are changing.

Since more and more business processes are going digital and more and more private data is being made, drug companies need to keep an eye on data security problems. Putting in place strong encryption, access controls, regular checks, and training programmes for workers are all ways to lower risks and make sure that data security laws are followed. There are different opinions, even though most of the people who answered are sure of the data security protocols. This shows that more money needs to be spent on cybersecurity measures to keep important data safe and people trusting the processes used to make sterile injectables.

Infrastructure Design Appropriateness

The study results on the fit of infrastructure design in Indian drug plants tell us useful things about the places where sterile injectable drug products can be manufactured. While some people disagreed, most of those who answered highly agreed that pharmaceutical plants have the right tools to manufacture sterile injectable drugs. This positive view is likely because people in the business have spent money on new buildings with safe technologies, HVAC systems, and other important structures that maintain sterile conditions in the required areas.

It is important to note, though, the small number of people who said they were not sure if the infrastructure plan was okay. Some people may have these views because they are worried about buildings that aren't working well, old infrastructure, or improper maintenance techniques. These issues might make sterile work environments less safe. To stay in line with the law and keep up high standards for product quality and safety, pharmaceutical companies need to make sure that their infrastructure is set up properly. The Good Manufacturing Practice

(GMP) laws tell facilities what rules they need to follow. These rules spell out exactly how cleanrooms should be set up, built, and run. Most of the people who answered are sure that the planning of the infrastructure is right. Having said that, the fact that people have different thoughts shows how important it is to keep looking at building design and making changes to create safe environments for the manufacture of sterile products.

Establishing validity and reliability

The validity and reliability of the survey results were assessed through various statistical analyses, including regression, correlation, and Cronbach's alpha score. The regression analysis was conducted to explore the relationships between different variables, such as quality control measures, staff training emphasis, and infrastructure design appropriateness. Significant relationships observed in the regression models indicate the validity of the survey findings, suggesting that the measured variables are indeed related and contribute to compliance with sterile injectable production regulations. Moreover, a correlation test was done with an aim of evaluating the strength and the directions of association between vital variables. The correlation among the different factors such as confidence in sterile conditions and effectiveness of quality control were tested and showed a strong to moderate results. Therefore, the outputs of the survey are validated by having these factors tested and producing good result only. Simplification of the analysis yielded evidence of the consistency of the implied links between the measured variables.

Furthermore, Cronbach’s Alpha coefficient was also calculated to explore and evaluate reliability and internal consistency of the survey results measuring the perceptions of the respondents. The value that was obtained was 0.759, and this was indication of the satisfactory level of reliability, suggesting the reliability and validity of the final outcome. Overall, the convergence of findings from regression, correlation, and reliability analyses enhances the validity and reliability of the survey results, providing confidence in the robustness of the conclusions drawn from the data.

4.4 Chapter Summary

The results section provides details on compliance risks that arise when the Indian pharmaceutical industry manufactures sterile drugs for injection. First, some history of the people who answered the survey is given. Next, how they felt about different aspects of similarity is looked at. The results give us a fuller picture of laws, how well people believe they can maintain sterile conditions, how important it is to train staff, how well quality control

measures work, data security processes, infrastructure design, and ways to lower risk. Different important links were found between different factors by using descriptive and inferential statistics. This helps us learn more about the compliance scene. From the survey, these results are put together and important points are highlighted, such as how important it is to have strong regulatory laws, and infrastructure plan, and always try to make things better. A lot of emphasis is put on how important it is to deal with compliance risks to keep pharmaceutical goods safe and of good quality. The politicians, business people, and governing groups all have to deal with it. This part adds to what is known in the field by giving a full report of the survey results. Further, it helps build plans to boost compliance in the Indian pharma business**.**

5 Conclusion and Recommendations

5.1 Chapter Overview

This chapter summarizes in detail the major outcomes, findings and suggestions for compliance risks in the Indian pharmaceutical industry. It points to the importance of ensuring regulatory issues are addressed, and the implementation of quality control measures that are best practice, together with the creation of a culture of compliance and accountability. The proposed study will be using in-depth research and through its engagement with the stakeholders, it will not only increase the environment where sterile injectable practices are being followed but also help in safeguarding the patients and promoting public health.

5.2 Linking with Objectives

To examine the rules that govern injectable sterile products in India, setting the groundwork for comprehending the necessary compliance.

The survey results showed that there are rules and laws in India that make it hard to make sterile injectable drugs. Based on how people thought about the current law systems and how well they work to make sure businesses follow the rules, the study gives us information about those systems. The study shows a snapshot of compliance by analyzing how confident people are that they can keep things clean, how important it is to train staff, and how well quality control methods work. These answers help to figure out what the law says is required to be done and point out places where changes may be made. The study's main goal was to find out more about the rules that guide injectable products in India. It has done this by helping those interested in learning more about those rules.

To locate and gather possible compliance risks connected with buildings, staff, quality control measures, and production methods for sterile injectable drugs.

Looking closely at the study's findings, it can be observed that the various compliance risks are connected with multiple parts of manufacturing sterile injectable drugs in India. The study finds and looks into possible risks related to buildings, staff, quality control measures, and ways of making things by asking people how they felt about these things. Some of these risks are how the infrastructure is built, how well the staff is trained, how well quality control measures work, and how well people follow the regulations set by the government. This helps reach the goal of finding and gathering information on possible trouble spots in the production process. This in-depth study helps everyone in the business understand the issues it meets and come up with

solutions to lower these risks to maintain the quality, safety, and efficacy of sterile injectable drugs in India.

To assess the potential impact of known compliance risks on the quality and safety of sterile injectable products, including how bad they are and what they mean for public health.

From the survey, we can gather a complete overview of how the quality and safety of manufactured products are affected by compliance risks. Results demonstrate, such issues like inappropriate infrastructure design, wrong training of personnel, and defects of quality control measures. For example, improper maintenance of the quality control procedures and data security laws creates a strong wind of panic where patient safety and reliability of the product may be compromised.

A major risk is that people might ignore the regulations of manufacturing sterile drugs, which could be hazardous to public health. A compliance risk questionnaire was used to achieve the purpose of this study, that is, to assess the extent of the negative impact on product quality or safety.

To create effective risk-reduction plans by studying and rating compliance risks and suggesting best practices and process enhancements.

This study helps planning that leads to the reduction of risks by closely looking at compliance risks. In the course of the research, the organization spots and assesses the risks in different departments like infrastructure, staff training, and quality assurance. They come up with these thoughts out of which they get ideas to carry out the tasks more effectively and efficiently. For instance, several innovative ideas could be incorporated to quality control measures, make sure that the staff training programs are still strong, and update their equipment to meet legal standards. They are useful insights for pharmaceutical partners and regulatory bodies which helps them to focus strategies that minimize compliance risks, improve product quality and safety and finally, results in the accomplishment of the common goal of a risk-reduction plan.

To support suggested risk-reduction strategies with real-life case studies from the Indian pharmaceutical industry, looking at examples of how compliance risks were handled well and the results of the strategies that were put in place.

For proposing methods that will be useful for reducing the level of risk, the research incorporated different real-life data within the Indian Pharmaceutical industry. The demonstration of different compliance measures and practices were demonstrated, and the

strategies to overcome them were also proposed. These show examples of how safety risks were found, dealt with, and handled well. Stakeholders can learn a lot about how well proactive risk management methods work by looking at the outcomes and effects of these strategies. In addition, these data show how strategic actions can work and produce results, encouraging others to use the same methods. By adding real-life cases to the results, the study meets its goal, at least in part, of adding some real-world knowledge from the industry to back up suggested risk-reduction tactics.

5.3 Limitations of the study

Even though the study gives us useful information about compliance risks and tactics in the Indian pharmaceutical business, it is important to note that it has some flaws that could make it harder to understand and use the results in other situations. First, the fact that the study relies on self-reported data from survey subjects means that answer bias and social preference bias could occur. People may give statements they think are socially accepted or that match what they think is expected of them, which can cause compliance problems to be over- or under-estimated. Besides this, the fact that self-reported data were used could be insufficient and the answers could not be the same which makes the result hard to trust. In addition, the research sample size (No. of participants- 49) could lessen its applicability when examining other situations. A range of people from different sectors of the pharmaceutical industry that were included in the study cannot present the exact evidence of the whole complexity of compliance issues in different domains, sectors and organizations. One of the main limitations of the research was the inference of the outcome based on only the Indian Pharmaceutical industry, and thus the result will not be applicable in other nations.

The study also only looked at the production of sterile injectable drugs, which means it might not be useful for other parts of the pharmaceutical business or for other kinds of medical goods. Different types of goods and production methods can pose very different compliance difficulties and risk factors. Because of this, care should be taken when applying the results to other situations. Lastly, the study's focus on numbers may mean that it does not fully address more subtle qualitative findings that could help us understand compliance problems better. Qualitative methods, like focus groups or conversations, could add to the numeric results by getting a lot of information about the situation and people's points of view.

5.4 Future Scope

This study found many areas that can be looked into further and used in the real-life setting when it comes to quality management and compliance. This is the first thing that could be studied in the future: the main things that lead to compliance risks and the best ways to lower those risks. Some qualitative methods, such as focus groups, interviews, and case studies, might help us learn more about the difficult steps and outside factors that impact the Indian pharmaceutical industry's compliance rules. Second, research needs to keep going to see how behavioural changes develop over time. Longitudinal studies help researchers see how well methods for lowering risks are working and find new problems with following the rules that appear when rules are changed. Researchers may also investigate how advances in technology like robotics and data analytics affect quality control and keeping track of compliance in the process of making medicines in the future. If new tools are used, compliance management could be faster, more accurate, and more open.

There is also a chance that people in the pharma industry, the government, and academic institutions could work together to find and share the best ways to make sure that pharma industries implement and follow the rules for the manufacturing**No table of figures entries found.** of drugs. People could share their thoughts and experiences more easily if there were places to share information, classes, and training courses. This would improve the safety mindset and skills of the business.

5.5 Recommendations

Enhance Regulatory Oversight: Reinforce regulatory frameworks and enforcement mechanisms, and make sure to abide by compliance standards to sustain that abidance. It will also involve routine inspections, audits and public announcements on the wrong-doing disclosures that are supposed to influence the consistent maintenance of quality and safety standards.

Implement Robust Training Programs: Consent all-inclusive training programs for personnel from pharmaceuticals who will acquire detailed knowledge about compliance regulations and best practices through such training programs. Hence, such programs, which should be subjected to areas such as sterilization techniques of production, quality control measures, and risk management strategies that would assist personnel to have the knowledge and skills they need, should be established.

Foster Collaboration and Knowledge Sharing: Enable the collaboration of the different industries' stakeholders with relevant agencies as well as academic institutions to share ideas, experiences, and best practices for compliance management. This in turn, could help create messaging boards, workshops, and discussion forums as a vehicle of indiscriminate learning and development in the business sector.

Invest in Technology and Innovation: Utilize technological advancements such as automation, digital analysis, and monitoring of data in compliance with the work processes for efficiency, accuracy in quality control and better risk management. The application of innovative techniques to observe the production procedures and identify and detect inconsistencies will be beneficial. By investing resources in cutting-edge technology, real-time monitoring of processes can be enabled, early warnings to be alerted and proactive work to minimize risks to be done.

Promote Industry-Wide Benchmarking: Spur pharmaceutical firms to assess their practices and increase compliance with industry production models and leading-edge practices. This is a way to detect which areas require assistance, architect solutions based on this input, and to foster a culture of continuous improvement. Establishing performance measurement and improving peers review systems can help drive companies to achieve the most appropriate standards in compliance management.

5.6 Chapter Summary

The industry is facing several challenges, including a shortage of skilled workforce, stringent regulations, short house time and supply chain management difficulties, that pose a risk to the compliance of sterile injectable production in the Indian pharmaceutical industry. Rigorous quantitative techniques, analysis of demographic data, regulatory perceptions, and observations of compliance measures revealed certain of major findings. On the other hand, the study proves that the industry professionals must deal with compliance risks through the importance of implementing robust risk-reduction strategies. In the future, society will invest in regulatory oversight, education, adapting to new technologies, developing collaboration among the stakeholders and providing industry-wide compliance guidelines for all those working in this field. In doing so, public health care will be elevated. By putting these recommendations into action, the industry will move forward to a stage of continuous improvement and ensuring drug quality and safety.

References:

Ali Khan, A., Munir, M., Miraj, F., Imran, S., Arif Siddiqi, D., Altaf, A., Khan, A.J. and Chandir, S., (2021). *Examining unsafe injection practices associated with auto-disable (AD) syringes: a systematic review*. Human vaccines & immunotherapeutics, 17(9), pp.3247-3258.

Almeter, P.J., Isaacs, J.T., Hunter, A.N., Henderson, B.S., Platt, T., Mitchell, B.J., Do, D., Brainard, A.B., Brown, J.E., Stone, R.M. and Nguyen, B.H., (2022). *FDA Approaches in Monitoring Drug Quality, Forces Impacting the Drug Quality, and Recent Alternative Strategies to Assess Quality in the US Drug Supply.* Journal of Pharmaceutical Innovation, 17(2), pp.269-282.

Biswal, S., (2020). *Drugs and cosmetics act, 1940 and interpretation of definitions*. Research Journal of Pharmacy and Life Sciences: Volume, 1(1), pp.1-9.

Bushra, F. and Tabassum, S., (2020). *Industrial training at Sanofi Bangladesh Limited* (Doctoral dissertation, Brac University).

Creelman, B., Frivold, C., Jessup, S., Saxon, G. and Jarrahian, C., (2022). *Manufacturing readiness assessment for evaluation of the microneedle array patch industry: an exploration of barriers to full-scale manufacturing.* Drug Delivery and Translational Research, pp.1-8.

Dmour, I., (2023). *Content analysis of US FDA warning letters issued to compounding pharmacies regarding violations of current good manufacturing practices between 2017 and (2022). Journal of Pharmaceutical Innovation*, *18*(3), pp.965-979.

Geyman, C. and Settanni, E., (2020). *Understanding risk in pharmaceutical supply chains.*

Gonella, A., Grizot, S., Liu, F., López Noriega, A. and Richard, J., (2022). *Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules.* Expert Opinion on Drug Delivery, 19(8), pp.927-944.

Graham, J., Yao, H. and Franklin, E., (2021). *Occupational exposure risks when working with protein therapeutics and the development of a biologics banding system.* Applied Biosafety, 26(4), pp.193-204.

Hout, S.A., (2021). *Sterile Processing of Pharmaceutical Products: Engineering Practice, Validation, and Compliance in Regulated Environments*. John Wiley & Sons.

Isaacs, J.T., Almeter, P.J., Henderson, B.S., Hunter, A.N., Platt, T.L. and Lodder, R.A., (2023). *Spectrometric Assessment of Generic and Brand Drug Quality for a Sentinel Screening Network*. *Applied Spectroscopy*, *77*(8), pp.915-927.

Jain, S.K. and Jain, R.K., (2021). *A study of regulatory agencies inspected global drug manufacturers*. Research Journal of Pharmacy and Technology, 14(2), pp.1008-1016.

Khemariya, P., (2024). *An Over View of Sterile Filtration Validation: A Key Elements for Sterile Drug Product Manufacturing*. Ann Clin Med Case Rep, 12(8), pp.1-4.

Kottapalli, P., Podduturi, N.C.R., Aswini, G., Jyothi, S. and Naveen, A., (2023). *Safe injection, infusion and medication-vial practices at a tertiary care centre: a quality improvement initiative.* GMS Hygiene and Infection Control, 18.

Krämer, I., Thiesen, J. and Astier, A., (2020). *Formulation and Administration of Biological Medicinal Products"*. Pharmaceutical Research, 37, pp.1-18.

kumar Dabhi, S. and Pandit, N.B., (2024). *A Comprehensive Examination of Injection Practices Across Varied Healthcare Facilities: A Focus on Patient Safety and Provider Adherence.* Pakistan Heart Journal, 57(1), pp.145-150.

Lirio, A.C.M., Diaz, V.A., Chellappan, D.K., Dua, K., Lourenço, F.R. and de Jesus Andreoli Pinto, T., (2023). *Development of a Statistical Approach for Microbial Monitoring in Non-sterile Pharmaceutical Environments.* Journal of Pharmaceutical Innovation, pp.1-9.

Lombardo, M., da Silva, C.M. and Lourenço, F.R., (2022). *Conformity assessment of medicines containing antibiotics–a multivariate assessment.* Regulatory Toxicology and Pharmacology, 136, p.105279.

Ma, C.Y., Zhai, Y., Li, C.T., Liu, J., Xu, X., Chen, H., Tse, H.F. and Lian, Q., (2023). *Translating mesenchymal stem cell and their exosome research into GMP compliant advanced therapy products: Promises, problems and prospects.* Medicinal Research Reviews.

Makwana, R.G., Desai, K.V., Kikani, V. and Vaja, M.D., (2021). *Regulatory advances and prospects of variation filing for the registered parenteral products in USA and Europe.* International Journal Of Drug Regulatory Affairs, 9(2), pp.52-65.

Manik, N., Davange, M. and Patil, D., (2023). *A Review On Advancements In The Packaging Of Medicines*. International Journal of Pharmaceutical Sciences, 1(12), pp.1-1.

Miglani, A., Saini, C., Musyuni, P. and Aggarwal, G., (2022). *A review and analysis of product recall for pharmaceutical drug product.* Journal of Generic Medicines, 18(2), pp.72-81.

Nayak, A., Katta, H., Thunga, G., Pai, R., Khan, S. and Kulyadi, G.P., (2022). *A critical analysis of labeling errors of high-alert medications–Safety assessment and remedial measures through case based approach.* Clinical Epidemiology and Global Health, 18, p.101161.

Nikam Nikita, R., Vaishnavi, A. and Lalchand, D., (2023). *Parenteral drug delivery approach: an overview*. *Journal of xidian university*, *17*(1), pp.386-400.

Panchal, K., Katke, S., Dash, S.K., Gaur, A., Shinde, A., Saha, N., Mehra, N.K. and Chaurasiya, A., (2023). *An expanding horizon of complex injectable products: Development and regulatory considerations.* Drug Delivery and Translational Research, 13(2), pp.433-472.

Pockle, R.D., Masareddy, R.S., Patil, A.S. and Patil, P.D., (2023). *A comprehensive review on pharmaceutical excipients*. *Therapeutic Delivery*, *14*(7), pp.443-458.

Ramani, V.K., Ganesha, D.V., Sarathy, V., Bhattacharjee, S., Ganeshan, S. and Naik, R., (2021). *Outbreak of Ralstonia mannitolilytica infection at a tertiary care oncology center in South India: a case series*. *Asian Pacific Journal of Cancer Biology*, *6*(1), pp.87-92.

Rampal, A. and Kanti, S.P., (2020). *Cosmetics in US and India: Overview of regulations and registration process*. International Journal of Drug Regulatory Affairs, 8(4), pp.20-24.

Salalli, R., Dange, J.R., Dhiman, S. and Sharma, T., (2023). *Vaccines development in India: advances, regulation, and challenges*. Clinical and Experimental Vaccine Research, 12(3), p.193.

Satheesh, S., Abimanyu, S. and Kamaraj, R., (2020). *Regulatory Challenges of Sterile Formulation Development As Per USFDA Prospectives.* Research Journal of Pharmacy and Technology, 13(3), pp.1511-1516.

Sawant, A., Kamath, S., Katta, H.G., Badamane, S.M., Shenoy, R. and Pai, G.K., (2022). *Investigation of manufacturing defects and cGMP lessons learnt from quality issues in Pharmaceutical Sterile Preparations*. *Research Journal of Pharmacy and Technology*, *15*(2), pp.729-735.

Seet, W.T., Mat Afandi, M.A., Ishak, M.F., Hassan, M.N.F., Ahmat, N., Ng, M.H. and Maarof, M., (2023). *Quality management overview for the production of a tissue-engineered human skin substitute in Malaysia*. Stem Cell Research & Therapy, 14(1), p.298.

Singha, S. and Mehtab, D., (2020). *Sterilization of pharmaceutical dosage forms. Drug Delivery Aspects: Volume 4: Expectations and Realities of Multifunctional Drug Delivery Systems, p.169.*

Sundar, D., Das, T., Chhablani, J., Kumar, A. and Sharma, N., (2020). *All India Ophthalmological Society members' survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection*. Indian Journal of Ophthalmology, 68(6), p.1095.

Tavares, M., Kozak, M., Balola, A. and Sá-Correia, I., (2020). *Burkholderia cepacia complex bacteria: a feared contamination risk in water-based pharmaceutical products*. *Clinical microbiology reviews*, *33*(3), pp.10-1128.

Wen, Y. and Jawa, V., (2021). *The impact of product and process related critical quality attributes on immunogenicity and adverse immunological effects of biotherapeutics*. *Journal of pharmaceutical sciences*, *110*(3), pp.1025-1041.